Clinical trials: Early-Stage Non-Small Cell Lung Cancer
Lung Cancer
High-Dose Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Trial name
- NCT00003284
- Testing
- filgrastim, carboplatin, etoposide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Herbert Irving Comprehensive Cancer Center
Non-small Cell Lung Cancer
Near-Infrared Fluorescence Guided Robotic Pulmonary Segmentectomy for Early Stage Lung Cancer
Lungs are made up of individual lobes. When a lung cancer tumour is detected in one of these lobes, surgeons typically perform a Lobectomy.
- Trial name
- NCT02570815
- Testing
- indocyanine green
- Where
- Canada
- Volunteers
- 250 people
- Sponsor
- St. Joseph's Healthcare Hamilton
Non-Small Cell Lung Cancer, Medullary Thyroid Cancer
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of selpercatinib (also known as LOXO-292) administered orally to participants…
- Conditions
- Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Any Solid Tumor
- Trial name
- LIBRETTO-001 (NCT03157128)
- Testing
- LOXO-292
- Where
- 85 sites in United States, Australia and 14 more
- Volunteers
- 857 people
- Sponsor
- Eli Lilly and Company
Non Small Cell Lung Cancer
Surgery for Early Lung Cancer With Preoperative Erlotinib (Tarceva): A Clinical Phase II Trial (SELECT)
2.5 Rationale for preoperative erlotinib therapy Erlotinib is the only EFGR tyrosine kinase inhibitor to demonstrate a survival advantage and symptom improvement in a large phase III trial after failure of chemotherapy in…
- Trial name
- SELECT (NCT00462995)
- Testing
- Erlotinib
- Where
- 2 sites in Canada
- Volunteers
- 25 people
- Sponsor
- University Health Network, Toronto
Non-Small Cell Lung Cancer, Stage IA Non-Small Cell Lung Cancer
Segmentectomy Versus Lobectomy for Deep Solid-Dominant Early-Stage NSCLC
SOLID is a multicenter, open-label, randomized, controlled, phase III non-inferiority trial comparing anatomic segmentectomy with lobectomy in patients with deeply located, solid-dominant, clinical stage IA non-small cell lung…
- Trial name
- SOLID (NCT07698990)
- Testing
- Anatomic Segmentectomy, Anatomic Lobectomy
- Where
- China
- Volunteers
- 1,200 people
- Sponsor
- Shanghai Chest Hospital
Inoperable Early Stage Non-small Cell Lung Cancer
Prediction of the Effectiveness of Hypofractionated Radiation Therapy in Early Stage Lung Cancer by Bio-imaging and Biomarkers
Surgical resection with mediastinal lymph node sampling is currently the therapy of choice for early stage (I-II) non-small cell lung cancer (NSCLC).
- Trial name
- PEARL-2 (NCT01138748)
- Testing
- hypofractionated radiation therapy
- Where
- Belgium
- Volunteers
- 5 people
- Sponsor
- University Hospital, Ghent
Stage IA Non-small Cell Lung Cancer, Adenocarcinoma of the Lung
Comparison of Different Types of Surgery in Treating Patients With Early-stage Non-small Cell Lung Cancer
The purpose of this study is to compare early-stage peripheral non-small cell lung cancer lobectomy and sub-lobectomy surgery to evaluate if sub-lobectomy is as feasible and effective for the treatment of early-stage (diameter…
- Conditions
- Stage IA Non-small Cell Lung Cancer, Adenocarcinoma of the Lung, Squamous Cell Lung Cancer
- Trial name
- NCT02288026
- Where
- China
- Volunteers
- 630 people
- Sponsor
- Capital Medical University
Carcinoma, Non-Small-Cell Lung
TAilored Post-Surgical Therapy in Early Stage NSCLC
Our hypothesis is that patients receiving therapy based on their baseline tumor ERCC1 levels and EGFR mutations would attain better disease free survival rates than patients in the control arm receiving noncustomized therapy.
- Trial name
- TASTE (NCT00775385)
- Testing
- Standard Chemotherapy, Customized Treatment
- Where
- 42 sites in France
- Volunteers
- 152 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8
Quality of Life Intervention to Inform Patient Decision-Making in Early-Stage Lung Cancer
This clinical trial studies the effect of a quality of life intervention on decision-making in patients with early-stage lung cancer who are undergoing standard of care surgery or stereotactic body radiation therapy (SBRT).
- Conditions
- Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8
- Trial name
- NCT05292521
- Testing
- Best Practice, Informational Intervention, Questionnaire Administration
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Roswell Park Cancer Institute
Recurrent Colon Cancer, Extensive Stage Small Cell Lung Cancer
Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer
RATIONALE: Vaccines made from mutated ras peptides may make the body build an immune response to and kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of a vaccine containing mutated ras peptides and an immune…
- Conditions
- Recurrent Colon Cancer, Extensive Stage Small Cell Lung Cancer, Stage III Pancreatic Cancer, Stage III Rectal Cancer
- Trial name
- NCT00019006
- Testing
- Detox-B adjuvant, ras peptide cancer vaccine
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Non-Small-Cell Lung
Honokiol in Early-Stage Resectable Non-Small Cell Lung Cancer
This is a Phase I Trial evaluating the safety of the dietary supplement honokiol for lung cancer chemoprevention. Female or male patients aged 18 years, or older, with early stage lung cancer who have been scheduled for curative…
- Trial name
- NCT06566443
- Testing
- Honokiol
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- The Methodist Hospital Research Institute
Early Lung Cancer
Serplulimab Combined With Cryoablation for Early-Stage Non-Small Cell Lung Cancer
The goal of this clinical trial is to learn if serplulimab combined with cryoablation can effectively treat early-stage non-small cell lung cancer (NSCLC) in adults who are not eligible for or decline surgery or radiotherapy.
- Trial name
- NCT07064876
- Testing
- Serplulimab, CT-guided Cryoablation
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Xi Junjie
Non-small Cell Lung Cancer
Phase I/II Study of Fractionated Stereotactic Radiotherapy for Early Stage Non-Small Cell Lung Cancer
A new type of treatment called stereotactic radiotherapy has recently been developed in hopes of improving the success of the treatment and improving the convenience to patients, while reducing the side effects.
- Trial name
- NCT00888823
- Testing
- Stereotactic Radiotherapy
- Where
- 2 sites in Canada
- Volunteers
- 13 people
- Sponsor
- AHS Cancer Control Alberta
Lung Cancer, Nonsmall Cell, Stage IIIA, Lung Cancer Non-Small Cell Stage IIIB
Psychosocial eHealth in Advanced Lung Cancer
Being diagnosed with cancer impairs many areas of a person's life. Although efficacious educational, emotional and social interventions exist in this regard, they often reach few survivors and late.
- Conditions
- Lung Cancer, Nonsmall Cell, Stage IIIA, Lung Cancer Non-Small Cell Stage IIIB, Lung Cancer Non-Small Cell Stage III, Lung Cancer Stage IV
- Trial name
- NCT05497973
- Testing
- E-health ecosystem of stepped psychosocial care, Usual psychosocial care
- Where
- Spain
- Volunteers
- 152 people
- Sponsor
- Institut Català d'Oncologia
Lung Cancer, Pulmonary Complications
S0229, Pulmonary Rehabilitation Education w/wo Exercise Training in Improving Physical Function in Patients Who Are Undergoing Chemo & RT for Locally Advanced Lung Cancer
RATIONALE: Pulmonary rehabilitation education and exercise training may improve physical function and quality of life in patients who are receiving treatment for lung cancer.
- Trial name
- NCT00090961
- Testing
- educational intervention, supervised exercise program
- Where
- 60 sites in United States
- Volunteers
- 2 people
- Sponsor
- SWOG Cancer Research Network
Carcinoma, Non-Small-Cell Lung
Prognostic Value of PD-L1 in NSCLC
This is an observational retrospective study. The primary objective is to investigate the expression and potential prognostic role of Programmed Death Ligand 1 (PD-L1) in tumor samples from 350 patients with early stage…
- Trial name
- NCT03078959
- Testing
- immunohistochemistry
- Volunteers
- 350 people
- Sponsor
- Fondazione Ricerca Traslazionale
Carcinoma, Non-Small-Cell Lung
Phase II Study Evaluating The Safety And Response To Neoadjuvant Dasatinib In Early Stage Non-Small Cell Lung Cancer
Src expression has been identified in a majority of Non-Small Cell Lung Cancer (NSCLC) cell lines and there is preclinical evidence that Src family kinases may be important in hypoxic growth and angiogenesis in NSCLC.
- Trial name
- TOP0706 (NCT00564876)
- Testing
- Dasatinib
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Duke University
Non-small Cell Lung Cancer
Carbon Ion Therapy for Peripheral Non-small Cell Lung Cancer
To investigate the efficacy of carbon ion therapy for stage Ia-IIa primary peripheral non-small cell lung cancer (NSCLC). The primary endpoint was progression-free survival (PFS), and the secondary endpoint was local control…
- Trial name
- NCT05613452
- Testing
- Carbon ion beam radiotherapy
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Shanghai Proton and Heavy Ion Center
Non Small Cell Lung Carcinoma
Study of an Early Change of a Chemotherapeutic Doublet Versus Four Cycles of Chemotherapy in Advanced Non Small Cell Lung Cancer
The optimal strategy in advanced non small cell lung cancer with stable disease is not well known. There is no published study assessing an early change of chemotherapeutic drugs in these patients.Accordingly, we conduct this…
- Trial name
- NCT00199758
- Testing
- cisplatin, Gemcitabine, Taxol
- Where
- 21 sites in France
- Volunteers
- 227 people
- Sponsor
- University Hospital, Limoges
Non-Small Cell Lung Cancer
Tissue Collection Study for Patients With Non-Small Cell Lung Cancer With Resectable Disease
A 15-gene lung signature was created to identify predictive and prognostic biomarkers for Non-Small Cell Lung Cancer (NSCLC) patients.
- Trial name
- NCT01450553
- Where
- 7 sites in United States
- Volunteers
- 450 people
- Sponsor
- Precision Therapeutics